Drugs / TC-E202
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05357027 | Aug 2022 → Jan 2026 | cervical carcinoma | TCRCure Biopharma Ltd. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TC-E202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05357027 ↗ |
| Known as | E6 TCR | “infusion of E6 TCR (TC-E202) cells” NCT05357027 ↗ |
| Modality | Cell therapy | “T cells genetically engineered with a TCR targeting HPV16 E6 (E6 TCR)” NCT05357027 ↗ |